download PDF - Newron

Board of Directors
Members of the Board of Directors
The Company’s by-laws establish that the Board shall consist of a minimum of four (4) and a
maximum of seven (7) members. As per December 31, 2011, the Board was comprised of five (5)
directors. All of these directors were elected on April 28, 2011, for a three-year term expiring
on the date of the shareholders’ meeting scheduled to approve Newron’s financial statements
for the year ending December 31, 2013. All Newron Board members are due for re-election at
the same time. Board members can be re-elected for an unlimited number of terms. In case of
replacements of Board members, the replacing new members take over the mandate for
the left period of the leaving member. The shareholders’ meeting elects the new members by
individual vote.
The following table sets forth certain information about the Company’s directors:
Name Position Member
since
Rolf Stahel
Luca Benatti
Francesco Parenti
Patrick Langlois
Hanns Moehler
Chairman, nonexecutive
director
Managing Director,
CEO, executive
director
Non-executive
director
Non-executive
director
Non-executive
director
Relevant external positions
2004 Former CEO of Shire Pharmaceuticals Group plc;
non-executive BoD chairman of Connexios Life
Sciences Pvt Ltd, Cosmo Pharmaceuticals S.p.A. and
EUSA Pharma Inc.; executive BoD chairman of
Chesyl Pharma Ltd; member of the Advisory Board
of Imperial Business School, Imperial College London
1998 Former Head of the Molecular Neurobiology
Department at Pharmacia & Upjohn S.p.A.;
non-executive BoD member of Erydel S.p.A.
1999 Former Chief Scientific Officer of Vicuron Pharmaceuticals;
partner and director in Livolsi & Partners
2008 Former CFO and Vice-Chairman of the Management
Board of Aventis; General Partner of PJL Conseils;
BoD member of Shire Pharmaceuticals Inc., Scynexis,
Nanobiotix and Exonhit Therapeutics
2008 Vice-Director of Swiss National Center of Neuroscience
Research, member of the Swiss Academy
of Medical Sciences and the European Academy of
Sciences; Professor em. University of Zurich and
Swiss Federal Institute of Technology (ETH)
Zurich
None of the non-executive members of the Board as per December 31, 2011, was a member of
Newron’s management in the three financial years preceding the current year. None of the
Board members had significant business connections with the Company or its subsidiaries,
unless mentioned below or in section “Compensation, Shareholdings and Loans”(page 29).
None of the Board members exercises official functions or holds political posts.
20 Newron Annual Report 2011